Tomoya Yokota

Sep 9, 2024 | dx.doi.org | Tomoya Yokota |Yan Yu |Takayoshi Arai |Kensuke Araseki

May 24, 2024 | nature.com | Jordi Rodon |Silvia Damian |Jesús García-Donas |Antoine Italiano |Iben Spanggaard |Tomoya Yokota | +1 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-02934-7, published online 6 May 2024In the version of the article initially published, patient numbers and ratios of the trial cohorts were missing from the abstract and have now been added in the HTML and PDF versions of the article.

May 6, 2024 | nature.com | Jordi Rodon |Silvia Damian |Jesús García-Donas |Antoine Italiano |Iben Spanggaard |Tomoya Yokota | +1 more

AbstractFibroblast growth factor receptor (FGFR) alterations drive oncogenesis in multiple tumor types. Here we studied pemigatinib, a selective, potent, oral FGFR1–FGFR3 inhibitor, in the phase 2 FIGHT-207 basket study of FGFR-altered advanced solid tumors. Primary end points were objective response rate (ORR) in cohorts A (fusions/rearrangements) and B (activating non-kinase domain mutations).

Nov 6, 2023 | bmccancer.biomedcentral.com | Tomoya Yokota |Sadamoto Zenda |Takeshi Kodaira |Naomi Kiyota |Yasushi Fujimoto |Koichiro Wasano | +7 more

Methods/designThis study is a multi-institutional, two-arm, open-label, randomized phase III study. The study protocol was reviewed by the Japan Clinical Oncology Group (JCOG) Protocol Review Committee and approved by as the JCOG1912 (NEW BRIDGE) in January 2021. The certificated review board approved in March 2021, and patient accrual was started at May 2021. The trial registry number is jRCTs031210100 (https://jrct.niph.go.jp/latest-detail/jRCTs031210100).

Sep 18, 2023 | pubs.acs.org | Tomoya Yokota |Qian Wang |Takahiro Sakurai |Kazuki Miwa

Download Hi-Res ImageDownload to MS-PowerPointCite This:J. Am. Chem. Soc. 2024, XXXX, XXXCCDC 2309448–2309449 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing [email protected], or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.